Abstract The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on β-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with β-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p=0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.
Introduction
Streptococcus pneumoniae remains a major cause of disease worldwide [1] . Among pneumonia pathogens, it is the most common cause of hospitalization in adults and the most frequent cause of death [2, 3] . Despite improvements in etiological diagnosis, effective antibiotic therapy, and advances in supportive care, the morbidity and mortality rates associated with pneumococcal pneumonia (PP) remain high. Case fatality rates for bacteremic pneumococcal pneumonia range between 7 and 35% [4] .
A recent study [5] of the factors associated with early death in patients with community-acquired pneumonia (CAP) reinforces the classical concept that some deaths are closely related to inadequate host response [6] . Excessive cytokine response in patients with severe CAP has been linked to deleterious effects and poor prognosis [7] [8] [9] [10] [11] [12] [13] [14] . However, most studies included populations that were heterogeneous in terms of patients, etiologies, and treatment. Significantly, specific studies on the role of cytokine response for predicting poor outcomes in patients with PP are scarce. In recent years, the modulation of the inflammatory response has emerged as a promising concept for improving the outcomes of CAP. Although it has been suggested that different antibiotic classes may have different effects on the systemic expression of cytokine production [15] [16] [17] , information addressing this issue in PP is lacking.
We carried out a prospective study in order to analyze the relationship between systemic expression of cytokine production and outcomes in patients with PP, and to compare the evolution of systemic cytokine levels over time in patients treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone).
Materials and methods

Study subjects and study design
The study was carried out in a 900-bed university hospital for adults in Barcelona, Spain. The hospital serves an area of 1,100,000 inhabitants and admits approximately 24,000 patients per year. All non-immunocompromised patients with PP who were admitted to the hospital from January 2005 through December 2005 were prospectively recruited and followed up. Patients with neutropenia, HIV infection or transplantation were not included. Concentrations of circulating cytokines were determined for all patients. To assess the effects of treatment on the systemic expression of cytokine production, patients were divided into two groups: those initially treated only with β-lactams (β-lactam group), and those initially treated with combination therapy including β-lactams plus fluoroquinolone (combination therapy group). This prospective longitudinal observational study was approved by the Ethics Committee of our Institution.
Clinical evaluation and follow-up
At the initial visit, and before starting empirical antibiotic therapy, patients provided a complete clinical history, and underwent physical examination and laboratory testing. Microbiological studies included two sets of blood cultures and sputum Gram stain and culture when available. Urinary antigen detection for S. pneumoniae was performed if indicated by the attending physician. Antimicrobial susceptibility was tested by the microdilution method, following the Clinical Laboratory Standard Institute methods and criteria [18, 19] .
Empiric antibiotic therapy was administered according to the hospital's guidelines, which recommend the administration of a ß-lactam agent (ceftriaxone or amoxicillinclavulanate) with or without a fluoroquinolone (levofloxacin). Combination therapy was recommended for patients with clinically suspected Legionella or an atypical pathogen, or in the case of severe CAP in the absence of a demonstrative sputum Gram stain. Levofloxacin monotherapy was allowed for selected cases (i.e., those patients with allergy to ß-lactam agents and no prior quinolone use).
Patients were seen daily during their hospital stay by one or more of the investigators who provided medical advice when requested and recorded demographic characteristics, underlying disease, clinical features, vaccination status, causative agents, therapy, and outcomes in a computerassisted protocol.
Definitions
Pneumococcal pneumonia was diagnosed in patients with signs and symptoms of an acute-onset lower respiratory tract infection, a new infiltrate on chest radiograph, and one or more cultures positive for S. pneumoniae obtained from blood, normally sterile fluids, or sputum and/or a positive test for detection of urinary antigen. Only good quality samples of sputum (<10 squamous epithelial cells and >25 leucocytes per field) were accepted for processing. S. pneumoniae was identified using standard microbiology procedures. S. pneumoniae antigen in urine was detected by using a rapid immunochromatographic assay (Now ™ ;
Binax, Portland, ME, USA). S. pneumoniae strains were serotyped. Molecular characterization was performed by pulsed field gel electrophoresis after restriction with Sma(I) and selected strains were analyzed by multilocus sequence typing (MLST), as previously reported [1] .
The diagnosis of septic shock was based on a systolic blood pressure of less than 90 mmHg and peripheral hypoperfusion with clinically suspected uncontrolled infection. Early death was defined as death due to any cause ≤48 h of hospitalization. Overall mortality was defined as that due to any cause within 30 days of hospitalization. The severity of illness at presentation was quantified using the validated PORT prediction rule for 30-day mortality and medical complications in CAP, as described elsewhere [20] .
Collection of blood samples and laboratory processing For all patients, serial venous blood samples were collected at inclusion, immediately prior to the initiation of antibiotic therapy, and on days 1, 2, 3, 5, and 7. The blood obtained was placed in tubes containing EDTA, immediately centrifugated, and stored at −80°C. The assays were performed by one of the authors (M.C.), who was blinded to the clinical details of individual patients. The circulating levels of cytokines IL-6, IL-8, IL-10, and TNF-α were measured.
The IL-6, IL-8, IL-10, and TNF-α concentrations were measured using commercially available kits (GENZYME, Cambridge, MA, USA). The procedure consisted of a solidphase chemiluminescent immunometric assay. The standards defined in the operator's manual were applied. The limits of detection were 3 pg/ml for IL-6, 1 pg/ml for IL-8, 4 pg/ml IL-10, and 0.5 pg/ml for TNF-α.
Statistical analysis
To analyze the relationship between systemic expression of cytokine production and the severity of PP we compared serial serum cytokine measurements in patients who had severity markers (bacteremia, ICU admission, and mortality) with those who did not. A comparison of serial cytokine measurements was made using the Kruskal-Wallis one-way analysis of variance nonparametric test. To assess the effects of treatment on the systemic expression of cytokine production, we compared the combination therapy and β-lactam groups. Patients who initially received other antibiotic treatments were excluded. To detect significant differences between groups we used the chi-squared test with continuity correction for categorical variables. Normally distributed data were compared by using unpaired t tests and the Mann-Whitney U test was used for analysis of variables with non-normal distribution. Studies evaluating serum concentrations of cytokines over time (the fall-down pattern) were performed using the general linear model for repeated-measures tests, considering both withinsubject and between-subject factors (differences attributable to antimicrobial therapy). The contrasts selected were "difference" and "polynomic" for within subject factors. The analysis was adjusted for potential confounding variables (use of corticosteroids or ICU admission). The data analyses were performed with SPSS software version 13.0. In all analyses, we considered p values less than 0.05 to be statistically significant.
Results
Characteristics of patients and evolution of cytokines over time Fifty-two hospitalized patients with PP were included. Their demographic characteristics and main clinical features are shown in Table 1 . The diagnosis of PP was established with the use of one or more of the following methods: blood culture (21 cases), sputum Gram stain and culture (20 cases), urinary antigen test (17 cases), and transthoracic needle aspiration (2 cases). All S. pneumoniae were IL-10 TNF-α Fig. 1 Sequential cytokine levels in patients with severe pneumococcal pneumonia. All cytokines except TNF-α showed a statistically significant trend toward a rapid decrease after 24-48 h susceptible to ciprofloxacin (MIC range 0.5 to 2 μg/ml) and to levofloxacin (MIC range 0.5 to 1 μg/ml). Using current non-meningeal breakpoints for beta-lactams, all strains were penicillin (MIC range ≤0.03 to 2 μg/ml), amoxicillin (MIC range ≤0.03 to 2 μg/ml), and cefotaxime (MIC range ≤0.03 to 1 μg/ml) susceptible. The most frequent serotypes were 3, 1, and 5, which accounted for 51.4% of strains. These serotypes were related to ST260 and ST180 for serotype 3, and ST306 for serotype 1.
Concentrations of all the cytokines studied were detected in peripheral venous blood samples in all patients, although with a wide range of values. Figure 1 shows the evolution of cytokines over time. At admission, IL-6 and IL-8 showed the highest values. When the variations in concentrations were analyzed over time, all cytokines except TNF-α, showed a statistically significant trend toward a rapid decrease after 24-48 h. TNF-α remained basically unmodified throughout the study period.
Clinical outcomes and their relationship with systemic cytokines
The main outcomes of patients are summarized in Table 2 . Mean time to defervescence was 2.19 days (SD 1.19). After the initial evaluation in the emergency department, 37 patients (71.2%) were admitted to a conventional hospital ward, whereas the other 15 (28.8%) were transferred to an intensive care unit (ICU). The median length of ICU stay was 7 days (range 2-72 days). The early and overall case fatality rates were 1.9% and 15.4% respectively. The evolution of systemic cytokines concentration over time in relation to bacteremia was determined, as well as ICU admission and mortality. Table 3 shows serum levels of cytokine on days 0, 1, and 2 in relation to these outcomes.
In summary, no significant differences in cytokine levels were found in patients with or without bacteremia. IL-6 was significantly higher in patients requiring ICU admission and in patients who died. High levels of IL-8, especially on day 1, were also documented in patients with ICU admission and in those who died. On day 0, the third quartile for IL-6 initial concentrations identified 83.3% non-survivors and only 16.2% survivors. Thus, at admission, an IL-6 level >5,206 pg/ml predicted mortality with a sensitivity of 100%, a specificity of 79.3%, a positive predictive value of 80.6%, and a negative predictive value of 100%. On day 1, levels of IL-6 >4,097 pg/ml predicted mortality with a sensitivity of 100%, a specificity of 100%, a positive predictive value of 80%, and a negative predictive value of 94.3%.
Effects of antibiotic treatment on cytokine production
To assess the effects of treatment on systemic cytokine production, we compared 19 patients in the β-lactam group (ceftriaxone in 15 cases and amoxicillin-clavulanate in 4) with 20 patients in the combination therapy group (ceftriaxone plus levofloxacin in all cases). Thirteen patients (5 initially treated with combination therapy [β-lactam plus macrolide], 4 initially treated with linezolid, and 4 initially treated with a single fluoroquinolone treatment were excluded from the analysis. There were no differences in the characteristics of the patients who were included and those who were excluded. Demographic characteristics, the main clinical features and outcomes of patients by treatment group are shown in Table 4 . Interestingly, no significant differences in demographic characteristics, vaccination status, time from pneumonia onset to inclusion, previous use of steroids, statins, nonsteroidal anti-inflammatory drugs, severity of infection, bacteremia and outcomes were found between the groups. Chronic heart and cerebrovascular diseases were more frequent in patients in the β-lactam group. Conversely, the presence of multilobar infiltrates was more frequent in the combination therapy group. As shown in Fig. 2 , the IL-6 decrease was more rapid in the combination therapy group, particularly in the first few days (p=0.016). TNF-α levels were lower in the combination therapy group, but the differences did not reach statistical significance. No differences in the evolution over time of IL-8 were detected. Conversely, levels of antiinflammatory cytokines (IL-10) remained higher (p<0.001) in the combination therapy group. All these differences remained significant after adjustment for the use of corticosteroids and ICU admission.
Discussion
Previous studies of CAP have noted that most cytokines can be detected in systemic circulation and show a significant pattern of decline in the first hours of treatment. Indeed, all cytokines studied in the present report were detected in venous blood samples in patients with PP at hospital admission. Thus, most patients developed a systemic extension of the initially compartmentalized immune response in the lung. Interestingly, all these cytokines, except for TNF-α, declined in the first 48 h.
These decreases correlate clinically with the time to clinical defervescence.
Previous studies have reported that an excess of proinflammatory cytokines is associated with poor prognosis of CAP [7] [8] [9] [10] [11] [12] [13] [14] . Our results showed a similar relationship between high levels of cytokines and poor outcomes in the specific population with PP. We demonstrated that levels of IL-6 on admission, as well as levels of IL-6 and IL-8 in the first 48 h, were the best markers for predicting poor outcomes, in agreement with previous studies analyzing any etiology of CAP. A recent study [11] found that the addition of biological markers such as C-reactive protein to severity scoring systems (PSI, CURB-65 and CRB-65) improves the 30-day mortality prediction. Further studies are currently needed to establish the potential role of IL-6 and IL-8 in supplementing prognosis scoring systems in order to achieve a more accurate identification of patients with a greater probability of death.
The most notable finding of this study was the difference in the cytokine profile between patients treated with β-lactam monotherapy and those treated with combination therapy. We found that combination therapy of a β-lactam Fig. 2 Evolution of IL-6 and IL-10 systemic concentrations by treatment group. IL-6 decreased faster in the combination therapy group (p=0.016). Conversely, levels of anti-inflammatory cytokines were higher in this group (p<0.001). This analysis has been adjusted for potential confounder variables (i.e., the use of corticosteroids or ICU admission) plus fluoroquinolone produced a faster decrease in IL-6 in the initial 48 h of treatment in patients with PP. Taking into account the relationship between IL-6 and poor prognosis for PP, the modulation of the expression of this cytokine may be a key point for improving patient outcomes. Whether combination therapy can improve outcomes in patients with CAP is a controversial issue [21] [22] [23] [24] [25] [26] . Moreover, most studies have used the combination of β-lactam plus macrolide, not β-lactam plus fluoroquinolone.
A possible explanation for the differences observed in the pattern of systemic cytokine production over time is that β-lactam cell wall activity causes the release of cell wall components, which act as potent inflammatory inducers [27] [28] [29] [30] . One hypothesis is that combination therapy offers more rapid microbial killing due to the presence of quinolones and hence shortens the exposure of the host to microbial products. Additionally, fluoroquinolones have an intrinsic immunomodulation effect that inhibits the production of certain pro-inflammatory cytokines [15] [16] [17] [18] 31] . The possible beneficial effects of fluoroquinolones on the systemic expression of cytokine response when combined with β-lactam therapy in patients with PP have not been previously explored, but our results suggest that their potential anti-inflammatory and immunomodulatory effects persist when combined with β-lactam. A previous study [8] explored the effects of fluoroquinolone monotherapy in modulating the cytokine response in patients with PP, finding that it achieved a faster decrease in serum TNF-α production at 120 h post-admission than β-lactam monotherapy.
Our study has limitations that should be acknowledged. First, the study was observational and included a relatively small number of patients. Second, only 4 patients were treated with fluoroquinolone monotherapy, precluding comparisons in the pattern of systemic expression of cytokine production. Finally, it should be emphasized that our aim was not to establish whether combination therapy of β-lactam plus fluoroquinolone has a clear impact on survival in the first hours after admission for PP. Therefore, our results should be interpreted with caution.
We found that IL-6, IL-8, and IL-10 were detected in venous blood samples in all patients with PP at hospital admission with a rapid decrease in the first 48 h, correlating with clinical defervescence. High levels of IL-6 were found in patients with the worst outcomes. Initial β-lactam and fluoroquinolone combination antibiotic therapy produced a faster decrease in this cytokine in the first 48 h.
